Author(s): Ferrario CM
More than a century of research on the reninangiotensin system (RAS) has uncovered the widespread involvement of angiotensin II (Ang II) in the pathophysiology of cardiovascular diseases. A number of outcomes-based mega trials utilising hard clinical endpoints have revealed beneficial effects of angiotensin receptor antagonists (AIIAs/ARBs) in patients with hypertension, heart failure, diabetic nephropathy, and post-myocardial infarction (MI). The results of these studies not only emphasise the importance of Ang II in the pathophysiology of these diseases but have provided the basis for an evidence-based approach for the use of AIIAs in clinical practice. It is hoped that the next 100 years of research into the RAS will uncover hitherto unimaginable therapeutic opportunities.
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/17083068
Author(s): Law MR, Morris JK, Wald NJ
Author(s): Mark AL
Author(s): Kim JR, Kiefe CI, Liu K, Williams OD, Jacobs DR Jr, et al.
Author(s): Cain AE, Khalil RA
Author(s): Cody RJ
Author(s): Sarzani R, Salvi F, Dessì-Fulgheri P, Rappelli A
Author(s): Simões E Silva AC, Flynn JT
Author(s): Atlas SA
Author(s): Mulatero P, Verhovez A, Morello F, Veglio F
Author(s): Kobori H, Nangaku M, Navar LG, Nishiyama A
Author(s): Mitchell KD, Botros FT, Navar LG
Author(s): Admiraal PJ, Danser AH, Jong MS, Pieterman H, Derkx FH, et al.